International union of pharmacology. LX. Retinoic acid receptors

Pharmacological Reviews

Volumn 58, Issue 4, 2006, Pages 712-725

  Germain, Pierre ^a   Chambon, Pierre ^a   Eichele, Gregor ^b   Evans, Ronald M ^c   Lazar, Mitchell A ^d   Leid, Mark ^e   De Lera, Angel R ^f   Lotan, Reuben ^g   Mangelsdorf, David J ^h   Gronemeyer, Hinrich ^a  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e OREGON STATE UNIVERSITY   (United States)

^f UNIVERSITY OF VIGO   (Spain)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL)CARBOXAMIDO]BENZOIC ACID; 4 [2 (5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL) 1 PROPENYL]BENZOIC ACID; 4 [2 [5,6 DIHYDRO 5,5 DIMETHYL 8 (4 METHYLPHENYL) 2 NAPHTHYL]ETHYNYL]BENZOIC ACID; 6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ALITRETINOIN; DNA METHYLTRANSFERASE INHIBITOR; FENRETINIDE; HISTONE DEACETYLASE INHIBITOR; ISOTRETINOIN; RETINOIC ACID; RETINOIC ACID RECEPTOR AFFECTING AGENT; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR BLOCKING AGENT; RETINOIC ACID RECEPTOR GAMMA; RETINOID; TAMIBAROTENE; TAZAROTENE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING AFFINITY; BONE DISEASE; CANCER; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL GROWTH; CHEMOPROPHYLAXIS; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; HEADACHE; HOMEOSTASIS; HUMAN; MORPHOGENESIS; NONHUMAN; ORGANOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSORIASIS; REVIEW; SIDE EFFECT; SKIN DISEASE; TERATOGENICITY; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

ANIMALS; BINDING, COMPETITIVE; GENE EXPRESSION; HUMANS; MUTATION; NEOPLASMS; RECEPTORS, RETINOIC ACID; RETINOIDS; SKIN DISEASES; TRETINOIN;

EID: 33751505837     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.58.4.4     Document Type: Review

References (111)

1. Altucci L, Clarke N, Nebbioso A, Scognamiglio A, and Gronemeyer H (2005) Acute myeloid leukemia: therapeutic impact of epigenetic drugs. Int J Biochem Cell Biol 37:1752-1762.
2. Altucci L and Gronemeyer H (2001) The promise of retinoids to fight against cancer. Nat Rev Cancer 1:181-193.
3. Aranda A and Pascual A (2001) Nuclear hormone receptors and gene expression. Physiol Rev 81:1269-1304.
4. Bachman KE, Park BH, Rhee I, Rajagopalan H, Herman JG, Baylin SB, Kinzler KW, and Vogelstein B (2003) Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell 3:89-95.
5. Bastien J and Rochette-Egly C (2004) Nuclear retinoid receptors and the transcription of retinoid-target genes. Gene 328:1-16.
6. Blomhoff R (1994) Transport and metabolism of vitamin A. Nutr Rev 52:S13-23.
7. Boncinelli E, Simeone A, Acampora D, and Mavilio F (1991) HOX gene activation by retinoic acid. Trends Genet 7:329-334.
8. Bourguet W, Vivat V, Wurtz JM, Chambon P, Gronemeyer H, and Moras D (2000) Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains. Mol Cell 5:289-298.
9. Castillo L, Milano G, Santini J, Demard F, and Pierrefite V (1997) Analysis of retinoic acid receptor β expression in normal and malignant laryngeal mucosa by a sensitive and routine applicable reverse transcription-polymerase chain reaction enzyme-linked immunosorbent assay method. Clin Cancer Res 3:2137-2142.
10. Chambon P (1996) A decade of molecular biology of retinoic acid receptors. FASEB J 10:940-954.
11. Chambon P (2005) The nuclear receptor superfamily: a personal retrospect on the first two decades. Mol Endocrinol 19:1418-1428.
12. Chapellier B, Mark M, Messaddeq N, Calleja C, Warot X, Brocard J, Gerard C, Li M, Metzger D, Ghyselinck NB, et al. (2002) Physiological and retinoid-induced proliferations of epidermis basal keratinocytes are differently controlled. EMBO (Eur Mol Biol Organ) J 21:3402-3413.
13. Chen JY, Clifford J, Zusi C, Starrett J, Tortolani D, Ostrowski J, Reczek PR, Chambon P, and Gronemeyer H (1996) Two distinct actions of retinoid-receptor ligands. Nature (Lond) 382:819-822.
14. Chen JY, Penco S, Ostrowski J, Balaguer P, Pons M, Starrett JE, Reczek P, Chambon P, and Gronemeyer H (1995) RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation. EMBO (Eur Mol Biol Organ) J 14:1187-1197.
15. Clarke N, Germain P, Altucci L, and Gronemeyer H (2004a) Retinoids: potential in cancer prevention and therapy. Expert Rev Mol Med 6:1-23.
16. Clarke N, Jimenez-Lara AM, Voltz E, and Gronemeyer H (2004b) Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL. EMBO (Eur Mol Biol Organ) J 23:3051-3060.
17. Clarke N, Nebbioso A, Altucci L, and Gronemeyer H (2005) TRAIL: at the center of drugable anti-tumor pathways. Cell Cycle 4:914-918.
18. Dawson MI (2004) Synthetic retinoids and their nuclear receptors. Curr Med Chem Anti-Cancer Agents 4:199-230.
19. Dawson MI, Chao WR, Pine P, Jong L, Hobbs PD, Rudd CK, Quick TC, Niles RM, Zhang XK, Lombardo A, et al. (1995) Correlation of retinoid binding affinity to retinoic acid receptor α with retinoid inhibition of growth of estrogen receptor-positive MCF-7 mammary carcinoma cells. Cancer Res 55:4446-4451.
20. de The H, Chomienne C, Lanotte M, Degos L, and Dejean A (1990a) The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus. Nature (Lond) 347:558-561.
21. de The H, Vivanco-Ruiz MM, Tiollais P, Stunnenberg H, and Dejean A (1990b) Identification of a retinoic acid responsive element in the retinoic acid receptor β gene. Nature (Lond) 343:177-180.
22. Degos L and Wang ZY (2001) All trans retinoic acid in acute promyelocytic leukemia. Oncogene 20:7140-7145.
23. Dolle P, Ruberte E, Leroy P, Morriss-Kay G, and Chambon P (1990) Retinoic acid receptors and cellular retinoid binding proteins. I. A systematic study of their differential pattern of transcription during mouse organogenesis. Development 110:1133-1151.
24. Dupe V, Davenne M, Brocard J, Dolle P, Mark M, Dierich A, Chambon P, and Rijli FM (1997) In vivo functional analysis of the Hoxa-1 3′ retinoic acid response element (3′RARE). Development 124:399-410.
25. Durand B, Saunders M, Leroy P, Leid M, and Chambon P (1992) All-trans and 9-cis retinoic acid induction of CRABPII transcription is mediated by RAR-RXR heterodimers bound to DR1 and DR2 repeated motifs. Cell 71:73-85.
26. Egger G, Liang G, Aparicio A, and Jones PA (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature (Lond) 429:457-463.
27. Fanjul A, Dawson MI, Hobbs PD, Jong L, Cameron JF, Harlev E, Graupner G, Lu XP, and Pfahl M (1994) A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature (Lond) 372:107-111.
28. Farboud B, Hauksdottir H, Wu Y, and Privalsky ML (2003) Isotype-restricted corepressor recruitment: a constitutively closed helix 12 conformation in retinoic acid receptors β and γ interferes with corepressor recruitment and prevents transcriptional repression. Mol Cell Biol 23:2844-2858.
29. 2 in F9 cells results in the loss of retinoic acid-associated growth arrest. J Biol Chem 274:26783-26788.
30. Feinberg AP and Tycko B (2004) The history of cancer epigenetics. Nat Rev Cancer 4:143-153.
31. Freemantle SJ, Spinella MJ, and Dmitrovsky E (2003) Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene 22:7305-7315.
32. Fujii H, Sato T, Kaneko S, Gotoh O, Fujii-Kuriyama Y, Osawa K, Kato S, and Hamada H (1997) Metabolic inactivation of retinoic acid by a novel P450 differentially expressed in developing mouse embryos. EMBO (Eur Mol Biol Organ) J 16:4163-4173.
33. Galvin SA, Gilbert R, Baker M, Guibal F, and Tuley MR (1998) Comparative tolerance of adapalene 0.1% gel and six different tretinoin formulations. Br J Dermatol 139 (Suppl 52):34-40.
34. Gehin M, Vivat V, Wurtz JM, Losson R, Chambon P, Moras D, and Gronemeyer H (1999) Structural basis for engineering of retinoic acid receptor isotype - selective agonists and antagonists. Chem Biol 6:519-529.
35. Germain P, Iyer J, Zechel C, and Gronemeyer H (2002) Coregulator recruitment and the mechanism of retinoic acid receptor synergy. Nature (Lond) 415:187-192.
36. Germain P, Kammerer S, Perez E, Peluso-Iltis C, Tortolani D, Zusi FC, Starrett J, Lapointe P, Daris JP, Marinier A, et al. (2004) Rational design of RAR-selective ligands revealed by RARβ crystal stucture. EMBO (Eur Mol Biol Organ) Rep 5:877-882.
37. Ghyselinck NB, Dupe V, Dierich A, Messaddeq N, Garnier JM, Rochette-Egly C, Chambon P, and Mark M (1997) Role of the retinoic acid receptor β (RARβ) during mouse development. Int J Dev Biol 41:425-447.
38. Giguere V, Ong ES, Segui P, and Evans RM (1987) Identification of a receptor for the morphogen retinoic acid. Nature (Lond) 330:624-629.
39. Glass CK and Rosenfeld MG (2000) The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14:121-141.
40. Grondona JM, Kastner P, Gansmuller A, Decimo D, Chambon P, and Mark M (1996) Retinal dysplasia and degeneration in RARbβ2/RARγ2 compound mutant mice. Development 122:2173-2188.
41. Hauksdottir H, Farboud B, and Privalsky ML (2003) Retinoic acid receptors β and γ do not repress, but instead activate target gene transcription in both the absence and presence of hormone ligand. Mol Endocrinol 17:373-385.
42. Holmes WF, Dawson MI, Soprano RD, and Soprano KJ (2000) Induction of apoptosis in ovarian carcinoma cells by AHPN/CD437 is mediated by retinoic acid receptors. J Cell Physiol 185:61-67.
43. Hong WK and Sporn MB (1997) Recent advances in chemoprevention of cancer. Science (Wash DC) 278:1073-1077.
44. Hu X and Lazar MA (2000) Transcriptional repression by nuclear hormone receptors. Trends Endocrinol Metab 11:6-10.
45. Kagechika H, Kawachi E, Hashimoto Y, Himi T, and Shudo K (1988) Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity. J Med Chem 31:2182-2192.
46. Kagechika H and Shudo K (2005) Synthetic retinoids: recent developments concerning structure and clinical utility. J Med Chem 48:5875-5883.
47. Kastner P, Mark M, and Chambon P (1995) Nonsteroid nuclear receptors: what are genetic studies telling us about their role in real life? Cell 83:859-869.
48. Kastner P, Mark M, Ghyselinck N, Krezel W, Dupe V, Grondona JM, and Chambon P (1997) Genetic evidence that the retinoid signal is transduced by heterodimeric RXR/RAR functional units during mouse development. Development 124:313-326.
49. Klein ES, Pino ME, Johnson AT, Davies PJ, Nagpal S, Thacher SM, Krasinski G, and Chandraratna RA (1996) Identification and functional separation of retinoic acid receptor neutral antagonists and inverse agonists. J Biol Chem 271:22692-22696.
50. Krezel W, Ghyselinck N, Samad TA, Dupe V, Kastner P, Borrelli E, and Chambon P (1998) Impaired locomotion and dopamine signaling in retinoid receptor mutant mice. Science (Wash DC) 279:863-867.
51. Kurokawa R, DiRenzo J, Boehm M, Sugarman J, Gloss B, Rosenfeld MG, Heyman RA, and Glass CK (1994) Regulation of retinoid signalling by receptor polarity and allosteric control of ligand bindig. Nature (Lond) 371:528-531.
52. Kurokawa R, Soderstrom M, Horlein A, Halachmi S, Brown M, Rosenfeld MG, and Glass CK (1995) Polarity-specific activities of retinoic acid receptors determined by a co-repressor. Nature (Lond) 377:451-454.
53. Lafyatis R, Kim SJ, Angel P, Roberts AB, Sporn MB, Karin M, and Wilder RL (1990) Interleukin-1 stimulates and all-trans-retinoic acid inhibits collagenase gene expression through its 5′ activator protein-1-binding site. Mol Endocrinol 4:973-980.
54. Laudet V and Gronemeyer H (2002) The Nuclear Receptor Facts Book, Academic Press, San Diego.
55. Leid M, Kastner P, and Chambon P (1992) Multiplicity generates diversity in the retinoic acid signalling pathways. Trends Biochem Sci 17:427-433.
56. Li E, Sucov HM, Lee KF, Evans RM, and Jaenisch R (1993) Normal development and growth of mice carrying a targeted disruption of the α1 retinoic acid receptor gene. Proc Natl Acad Sci USA 90:1590-1594.
57. Lin RJ, Egan DA, and Evans RM (1999) Molecular genetics of acute promyelocytic leukemia. Trends Genet 15:179-184.
58. Lippman SM and Lotan R (2000) Advances in the development of retinoids as chemopreventive agents. J Nutr 130:479S-482S.
59. Lippman SM, Lotan R, and Schleuniger U (1997) Retinoid-interferon therapy of solid tumors. Int J Cancer 70:481-483.
60. Lohnes D, Kastner P, Dierich A, Mark M, LeMeur M, and Chambon P (1993) Function of retinoic acid receptor γ in the mouse. Cell 73:643-658.
61. Lotan R (1996) Retinoids in cancer chemoprevention. FASEB J 10:1031-1039.
62. Lotan R, Dawson MI, Zou CC, Jong L, Lotan D, and Zou CP (1995a) Enhanced efficacy of combinations of retinoic acid- and retinoid X receptor-selective retinoids and alpha-interferon in inhibition of cervical carcinoma cell proliferation. Cancer Res 55:232-236.
63. Lotan R, Xu XC, Lippman SM, Ro JY, Lee JS, Lee JJ, and Hong WK (1995b) Suppression of retinoic acid receptor-β in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med 332:1405-1410.
64. Loudig O, Babichuk C, White J, Abu-Abed S, Mueller C, and Petkovich M (2000) Cytochrome P450RAI(CYP26) promoter: a distinct composite retinoic acid response element underlies the complex regulation of retinoic acid metabolism. Mol Endocrinol 14:1483-1497.
65. Lufkin T, Lohnes D, Mark M, Dierich A, Gorry P, Gaub MP, LeMeur M, and Chambon P (1993) High postnatal lethality and testis degeneration in retinoic acid receptor α mutant mice. Proc Natl Acad Sci USA 90:7225-7229.
66. Mangelsdorf DJ and Evans RM (1995) The RXR heterodimers and orphan receptors. Cell 83:841-850.
67. Mark M, Ghyselinck NB, and Chambon P (2004) Retinoic acid signalling in the development of branchial arches. Curr Opin Genet Dev 14:591-598.
68. Mark M, Ghyselinck NB, and Chambon P (2006) Function of retinoid nuclear receptors: lessons from genetic and pharmacological dissections of the retinoic acid signalling pathway during mouse embryogenesis. Annu Rev Pharmacol Toxicol 46:451-480.
69. Mark M, Ghyselinck NB, Wendling O, Dupe V, Mascrez B, Kastner P, and Chambon P (1999) A genetic dissection of the retinoid signalling pathway in the mouse. Proc Nutr Soc 58:609-613.
70. Marks R (1997) Clinical safety of tazarotene in the treatment of plaque psoriasis. J Am Acad Dermatol 37:S25-S32.
71. McCaffery P and Drager UC (2000) Regulation of retinoic acid signaling in the embryonic nervous system: a master differentiation factor. Cytokine Growth Factor Rev 11:233-249.
72. McClelland PB (1998) Obtaining the optimal treatment outcome with tazarotene. Dermatol Nurs 10:343-348.
73. McKenna NJ and O'Malley BW (2002) Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108:465-474.
74. Nagy L, Kao HY, Chakravarti D, Lin RJ, Hassig CA, Ayer DE, Schreiber SL, and Evans RM (1997) Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 89:373-380.
75. Nicholson RC, Mader S, Nagpal S, Leid M, Rochette-Egly C, and Chambon P (1990) Negative regulation of the rat stromelysin gene promoter by retinoic acid is mediated by an AP1 binding site. EMBO (Eur Mol Biol Organ) J 9:4443-4454.
76. Niederreither K, Abu-Abed S, Schuhbaur B, Petkovich M, Chambon P, and Dolle P (2002) Genetic evidence that oxidative derivatives of retinoic acid are not involved in retinoid signaling during mouse development. Nat Genet 31:84-88.
77. Ortiz MA, Bayon Y, Lopez-Hernandez FJ, and Piedrafita FJ (2002) Retinoids in combination therapies for the treatment of cancer: mechanisms and perspectives. Drug Resist Updat 5:162-175.
78. Pavri R, Lewis B, Kim TK, Dilworth FJ, Erdjument-Bromage H, Tempst P, de Murcia G, Evans R, Chambon P, and Reinberg D (2005) PARP-1 determines specificity in a retinoid signaling pathway via direct modulation of mediator. Mol Cell 18:83-96.
79. Perissi V and Rosenfeld MG (2005) Controlling nuclear receptors: the circular logic of cofactor cycles. Nat Rev Mol Cell Biol 6:542-554.
80. Petkovich M, Brand NJ, Krust A, and Chambon P (1987) A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature (Lond) 330:444-450.
81. Petty WJ, Li N, Biddle A, Bounds R, Nitkin C, Ma Y, Dragnev KH, Freemantle SJ, and Dmitrovsky E (2005) A novel retinoic acid receptor β isoform and retinoid resistance in lung carcinogenesis. J Natl Cancer Inst 97:1645-1651.
82. Picard E, Seguin C, Monhoven N, Rochette-Egly C, Siat J, Borrelly J, Martinet Y, Martinet N, and Vignaud JM (1999) Expression of retinoid receptor genes and proteins in non-small-cell lung cancer. J Natl Cancer Inst 91:1059-1066.
83. Privalsky ML (2001) Regulation of SMRT and N-CoR corepressor function. Curr Top Microbiol Immunol 254:117-136.
84. Rastinejad F (2001) Retinoid X receptor and its partners in the nuclear receptor family. Curr Opin Struct Biol 11:33-38.
85. Rastinejad F, Wagner T, Zhao Q, and Khorasanizadeh S (2000) Structure of the RXR-RAR DNA-binding complex on the retinoic acid response element DR1. EMBO (Eur Mol Biol Organ) J 19:1045-1054.
86. Renaud JP, Rochel N, Ruff M, Vivat V, Chambon P, Gronemeyer H, and Moras D (1995) Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid. Nature (Lond) 378:681-689.
87. Resche-Rigon M and Gronemeyer H (1998) Therapeutic potential of selective modulators of nuclear receptor action. Curr Opin Chem Biol 2:501-507.
88. Rochette-Egly C (2003) Nuclear receptors: integration of multiple signalling pathways through phosphorylation. Cell Signal 15:355-366.
89. Rochette-Egly C and Chambon P (2001) F9 embryocarcinoma cells: a cell autonomous model to study the functional selectivity of RARs and RXRs in retinoid signaling. Histol Histopathol 16:909-922.
90. Schule R, Umesono K, Mangelsdorf DJ, Bolado J, Pike JW, and Evans RM (1990) Jun-Fos and receptors for vitamins A and D recognize a common response element in the human osteocalcin gene. Cell 61:497-504.
91. Smith WC, Nakshatri H, Leroy P, Rees J, and Chambon P (1991) A retinoic acid response element is present in the mouse cellular retinol binding protein I (mCRBPI) promoter. EMBO (Eur Mol Biol Organ) J 10:2223-2230.
92. Sporn MB, Dunlop NM, Newton DL, and Smith JM (1976) Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 35:1332-1338.
93. Sporn MB, Roberts AB, and Goodman DS (1994) The Retinoids: Biology, Chemistry and Medicine, Raven Press, New York.
94. Sun SY and Lotan R (2002) Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 41:41-55.
95. Tabin C (1995) The initiation of the limb bud: growth factors, Hox genes, and retinoids. Cell 80:671-674.
96. Takeuchi M, Yano T, Omoto E, Takahashi K, Kibata M, Shudo K, Harada M, Ueda R, and Ohno R (1998) Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: clinical experience with a new synthetic retinoid, Am-80. Leuk Lymphoma 31:441-451.
97. Taneja R, Rochette-Egly C, Plassat JL, Penna L, Gaub MP, and Chambon P (1997) Phosphorylation of activation functions AF-1 and AF-2 of RAR α and RAR γ is indispensable for differentiation of F9 cells upon retinoic acid and cAMP treatment. EMBO (Eur Mol Biol Organ) J 16:6452-6465.
98. Taneja R, Roy B, Plassat JL, Zusi CF, Ostrowski J, Reczek PR, and Chambon P (1996) Cell-type and promoter-context dependent retinoic acid receptor (RAR) redundancies for RARβ2 and Hoxa-1 activation in F9 and P19 cells can be artefactually generated by gene knockouts. Proc Natl Acad Sci USA 93:6197-6202.
99. Thacher SM, Vasudevan J, and Chandraratna RA (2000) Therapeutic applications for ligands of retinoid receptors. Curr Pharm Des 6:25-58.
100. Tobita T, Takeshita A, Kitamura K, Ohnishi K, Yanagi M, Hiraoka A, Karasuno T, Takeuchi M, Miyawaki S, Ueda R, et al. (1997) Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood 90:967-973.
101. Vivat-Hannah V and Zusi FC (2005) Retinoids as therapeutic agents: today and tomorrow. Mini Rev Med Chem 5:755-760.
102. Westin S, Kurokawa R, Nolte RT, Wisely GB, McInerney EM, Rose DW, Milburn MV, Rosenfeld MG, and Glass CK (1998) Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators. Nature (Lond) 395:199-202.
103. Weston AD, Blumberg B, and Underhill TM (2003) Active repression by unliganded retinoid receptors in development: less is sometimes more. J Cell Biol 161:223-228.
104. White JA, Beckett-Jones B, Guo YD, Dilworth FJ, Bonasoro J, Jones G, and Petkovich M (1997) cDNA cloning of human retinoic acid-metabolizing enzyme (hP450RAI) identifies a novel family of cytochromes P450. J Biol Chem 272:18538-18541.
105. Widschwendter M, Berger J, Daxenbichler G, Muller-Holzner E, Widschwendter A, Mayr A, Marth C, and Zeimet AG (1997) Loss of retinoic acid receptor β expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer. Cancer Res 57:4158-4161.
106. Wolbach SB and Howe PR (1925). Tissue changes following deprivation of fat-soluble A vitamin. J Exp Med 43:753-777.
107. Xu XC, Sneige N, Liu X, Nandagiri R, Lee JJ, Lukmanji F, Hortobagyi G, Lippman SM, Dhingra K, and Lotan R (1997a) Progressive decrease in nuclear retinoic acid receptor β messenger RNA level during breast carcinogenesis. Cancer Res 57:4992-4996.
108. Xu XC, Sozzi G, Lee JS, Lee JJ, Pastorino U, Pilotti S, Kurie JM, Hong WK, and Lotan R (1997b) Suppression of retinoic acid receptor β in non-small-cell lung cancer in vivo: implications for lung cancer development. J Natl Cancer Inst 89:624-629.
109. Zhu XJ, Tu P, Zhen J, and Duan YQ (2001) Adapalene gel 0.1%: effective and well tolerated in the topical treatment of acne vulgaris in Chinese patients. Cutis 68:55-59.
110. Zouboulis CC (2001) Retinoids - which dermatological indications will benefit in the near future? Skin Pharmacol Appl Skin Physiol 14:303-315.
111. Zusi FC, Lorenzi MV, and Vivat-Hannah V (2002) Selective retinoids and rexinoids in cancer therapy and chemoprevention. Drug Discov Today 7:1165-1174.